Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Nurix enrolled the first patient in a Phase 1b/2 study testing BTK degrader bexobrutideg with venetoclax in CLL/SLL. Trial results have not been presented; data are expected to guide future registrational development plans across CLL treatment lines. Initial focus is relapsed or refractory CLL, with potential expansion
Nurix Therapeutics has enrolled the first patient in a Phase 1b/2 combination study for bexobrutideg in chronic lymphocytic leukemia (CLL). The initial cohort will focus on relapsed/refractory CLL patients, with potential expansion to first-line CLL. The study will also evaluate bexobrutideg in combination with venetoc
Nurix Therapeutics said the first patient has been enrolled in its Phase 1b/2 combination study of bexobrutideg in chronic lymphocytic leukemia.